HEALTH AND SAFETY

» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing

 

More Information on Drug Promotion

Letter in the BMJ on Disease Mongering

Déjà Vu All Over Again


This Letter to the Editor by Peter Lurie, M.D., MPH, et al appeared in the July 27, 2002 edition of the
British Medical Journal

EDITOR . . . Moynihan et al's article on disease mongering by the pharmaceutical industry[1] reminded us of an old Bronx baseball saying, originating with Yogi Berra: "It's déjà vu all over again." 3M has for years sponsored the 3M/National Vaginitis Association (www.vaginalinfections.com). This produces a newsletter for health professionals (the Vaginitis Report) and materials for patients. Like the groups described by Moynihan et al, the 3M/ National Vaginitis Association is ostensibly an educational resource run by health professionals. 

Unfortunately, its activities include a large element of disease mongering. Mild symptoms are offered as portents of serious disease, and doctors are encouraged to be aggressive in their attempts to diagnose and treat vaginal infections, specifically bacterial vaginosis. As luck would have it, 3M produces a drug that treats bacterial vaginosis. More recently, the 3M/National Vaginitis Association established a free telephone number to distribute a free "educational brochure" promoted by a television personality. 

The association provides a further example of what Moynihan et al describe as using statistics to "maximise the size of a medical problem." A survey sponsored by the association found that "one-third of women believe that vaginal odor is normal, and approximately 24% believe that it's normal to experience vaginal itching."[2] This is offered as evidence of women's "lack of knowledge" about vaginal health. The association's website encourages women to contact a healthcare provider when they experience such symptoms. 

In fact, good evidence from the primary literature says that both odour and itching occur in women without vaginal complaints.[3],[4] The idea that vaginal complaints are due to infectious agents has been heavily promoted by 3M through the association and is implicit in the very naming of its website, which refers to vaginal infections. Yet we know that many women with vaginal complaints do not have an identifiable infectious pathogen.[5] 

It is time for clinicians to rethink the almost reflexive response, encouraged by the pharmaceutical industry and its front groups, of reaching for the prescription pad when a patient presents with vaginal complaints. As Yogi Berra also said: "You can observe a lot just by watching."

Matthew Anderson
Assistant Professor 
andersonma@aol.com 

Alison Karasz
Assistant Professor 
Montefiore Medical Center, Bronx, NY 10458, USA

Peter Lurie
Deputy Director
Public Citizen's Health Research Group, Washington, DC 20009, USA



References


[1] Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering [with commentary by P C Gøtzsche]. BMJ 2002; 324: 886-891 [Full Text]. (13 April.)  

[2]  3M/National Vaginitis Association. National survey reveals most women still are unaware of bacterial vaginosis (BV), the most common vaginal infection. St Paul, MN: 3M/NVA, 2002. (21 February 2002.)

[3]  Doty RL, Huggins GR. Changes in the intensity and pleasantness of human vaginal odors during the menstrual cycle. Science 1975; 190: 1316-1318 [Medline].

[4]  Priestley C, Jones B, Dhar J, Goodwin L. What is normal vaginal flora? Genitourinary Med 1997; 73: 23-28.

[5]  Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. MMWR 1998;47(RR-1).

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.